趋化因子及其受体转导途径与肿瘤的生长

肿瘤基质细胞及肿瘤细胞分泌的趋化因子,可通过肿瘤细胞表面受体,直接或间接途径促进肿瘤细胞的增殖、迁移、新生血管的形成,促进肿瘤的生长。一些外源趋化因子通过转基因抑制肿瘤的生长,为肿瘤治疗提供新的靶向。本主要综述趋化因子及其受体在肿瘤生长及信号转导方面的作用。     

肿瘤浸润转移分子机制的研究进展

肿瘤浸润转移是多因素参与、多步骤完成的生物化学变化过程。人们已经逐渐认识到浸润转移不仅与肿瘤细胞有关,更是肿瘤细胞和肿瘤组织微环境复杂的相互作用的结果,其过程涉及多个分子作用机制和信号转导途径,包括细胞和细胞的黏附分子、细胞外基质降解、生长因子、趋化因子和淋巴血管生成因子等。本文综述了肿瘤浸润转移的分子机制。     

趋化因子SDF-1及受体CXCR4研究进展

趋化因子(chemokine)是一类一级结构相似,以对白细胞等多种细胞具有趋化定向运动作用为特征的小分子蛋白。功能研究表明,趋化因子在胚胎发育、血管生成、炎症、肿瘤、艾滋病等机体多种生理和病理过程中发挥重要作用,部分趋化因子的衍生物或抑制物具有潜在的临床应用前景。不久的将来,趋化因子及其受体可能成为疾病治疗的分子靶点。     

趋化因子及趋化因子受体3在自身免疫疾病中的作用

人体在防御和清除入侵病原体等异物时,有一种使白细胞趋集的功能,有一些低分子量的物质能引起这种功能称之为趋化剂或趋化因子。这些小蛋白因其有定向细胞趋化作用而得名。经研究表明,趋化因子受体3（CXCR3）趋化因子可能在自身免疫内分泌疾病中起到致病作用。此外,血清中CXCR3趋化因子的判定可能辅助检测免疫活性。CXCR3和优先参与趋化Th1细胞的因子。该受体连接的趋化因子10（CXCL10）不仅参与白细胞募集,还诱导T细胞增殖的异源体和抗原的刺激。趋化因子10正调节Th1细胞产物并且负调节Th2细胞的产物。免疫反应纤维结合素（INF）产物可增强特异的炎症反应。当被激活或者发现炎症和肿瘤细胞后趋化因子受体3-B在内皮细胞中表达并且其结合的趋化因子10,趋化因子9和趋化因子11激活后产生血管抑制作用。     

趋化因子受体CXCR1、CXCR2与肿瘤研究进展

趋化因子受体是由7个跨膜区组成的G蛋白偶联受体,多个系统的肿瘤细胞均表达趋化因子受体,其在肿瘤的发生、发展和转移等各个阶段都发挥重要作用.近年来有不少研究发现趋化因子受体中的CXCR1和CXCR2与肿瘤关系密切,认为其可能成为肿瘤治疗的一个潜在新靶点.本文就CXCR1和CXCR2这两种趋化因子受体与肿瘤的关系做一综述.     

趋化因子ENA-78与肾脏疾病

体外实验中,各种肾脏细胞都能在特定刺激下表达趋化因子及受体。动物模型和人类肾脏疾病的肾组织中,炎症细胞浸润同时出现趋化因子及受体表达增多。ENA-78是一种来源广泛、生物功能多样的趋化因子,通过与其受体相互作用,引起中性粒细胞等白细胞的趋化、活化,参与肾脏疾病的发生、发展。     

单核细胞趋化蛋白—1生物学特性及应用研究

趋化因子是不同类型细胞分泌的低分子量 (8～ 1 0ｋＤ)的细胞因子 ,它们对各种白细胞亚类如中性粒白细胞、单核细胞、淋巴细胞具有趋化作用。根据其 4个保守的半胱氨酸残基中前两个的位置 ,可将它们分成ＣＣ、ＣＸＣ、ＣＸ3Ｃ、Ｃ等 4个亚家族。趋化因子具有以下几个特点 :(1 )趋化因子在体外趋化一种或多种髓样细胞 ,(2 )脂多糖 (ＬＰＳ)、肿瘤坏死因子 (ＴＮＦ)、白介素 1 (ＩＬ 1 )、前炎症刺激物可导致大多数趋化因子的产生和分泌 ,(3 )动物皮内注射趋化因子均可引起炎症浸润[1] 。1 .单核细胞趋化蛋白 1 (ＭＣＰ 1 )生物学功能单核细胞…     

细胞因子在动脉粥样硬化发生发展中的作用

细胞因子在动脉粥样硬化的发生发展中起关键性的作用.本丈综述了白细胞介素、肿瘤坏死因子、干扰素、集落刺激因子、转化生长因子和趋化因子6大细胞因子在动脉粥样硬化过程中的作用,为认识动脉粥样硬化的发生发展及治疗打下基础.     

趋化因子及其受体在神经系统发育中的作用

趋化因子是具有趋化作用的一类细胞因子,参与白细胞迁移的调控,在炎症中诱导性表达,与炎症过程密切相关,最初的研究主要局限于免疫系统。近几年来研究发现,趋化因子不仅参与神经系统疾病的炎症过程,而且在神经细胞成熟、发育等生理情况下组成性表达,发挥重要的生理调节作用,这一有趣的现象日益成为关注的焦点。本文主要针对趋化因子及其受体在神经系统发育中的作用及相关机制的研究成果予以综述,将有助于深入理解趋化因子与神经系统发育的关系,为进一步的研究提供依据。     

趋化因子CXCL9/Mig的研究进展

趋化因子CXCL9又称为mig,即monokine induced by IFN-γ(IFN-γ诱导的单核因子),是趋化因子CXC亚族的一员,体内主要由IFN-γ刺激的巨噬细胞和神经胶质细胞产生,体外则可由内皮细胞、粒细胞等在IFN-γ和TLR配体协同作用下产生。CXCL9的受体CXCR3为七次跨膜的G蛋白偶联受体。CXCL9对激活的T淋巴细胞和肿瘤浸润淋巴细胞具有趋化作用,但是对粒细胞和单核细胞没有作用。本文主要就CXCL9的结构与生化特征,其在免疫、移植排斥、肿瘤治疗等方面所起的作用,进行了较为系统的综述。     

Chemokines in tumor development and progression

Chemokines were originally identified as mediators of the inflammatory process and regulators of leukocyte trafficking. Subsequent studies revealed their essential roles in leukocyte physiology and pathology. Moreover, chemokines have profound effects on other types of cells associated with the inflammatory response, such as endothelial cells and fibroblasts. Thus, chemokines are crucial for cancer-related inflammation, which can promote tumor development and progression. Increasing evidence points to the vital effects of several chemokines on the proliferative and invasive properties of tumor cells. The wide range of activities of chemokines in tumorigenesis highlights their roles in tumor development and progression.     

Hidden malignant cells within leukocyte aggregates: seeds for invasive and metastatic cancer?

Background: Our previous studies revealed that leukocyte infiltration into aged or injured myoepithelial cell layers is a key trigger for breast tumor invasion and metastasis. Our current study further assessed the possibility that leukocyte aggregates may harbor detached individual tumor cell or clusters of tumor cells. Materials and methods: Tissue sections from patients with pregnancy-associated breast cancer (PABC) and controls were subjected to morphological and immunohistochemical assessment with a panel of leukocyte and tumor cell related markers. Results: A total of 63 leukocyte aggregates were detected in the 20 PABC cases studied. Of these, 55 (87%) were distributed within normal or hyperplastic lobules adjacent to invasive lesions. Over 70% of these leukocyte aggregates harbored detached individual tumor cell or cell clusters with malignant properties, including strong p53 positivity, elevated proliferation, reduced cell surface adhesion molecules, and cytological resemblance to adjacent invasive cancer cells. A significant number of these tumor cells or condensed chromosomes of mitotic tumor cells were observed to conjoin with the plasma membrane of leukocytes. Similar alterations were seen in leukocyte aggregates within the inter-lobular space and in non-PABC with a lower frequency. Conclusions: These findings suggest that leukocyte infiltration may trigger dissemination of tumor cells from their primary site, and that leukocyte aggregates may serve as a reservoir for disseminated tumor cells that may be physically dragged to distant sites by leukocytes during their migration.     

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Specialized immune cells that infiltrate the tumor microenvironment regulate the growth and survival of neoplasia.  Malignant cells must elude or subvert anti-tumor immune responses in order to survive and flourish. Tumors take advantage of a number of different mechanisms of immune “escape,” including the recruitment of tolerogenic DC, immunosuppressive regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSC) that inhibit cytotoxic anti-tumor responses. Conversely, anti-tumor effector immune cells can slow the growth and expansion of malignancies: immunostimulatory dendritic cells, natural killer cells which harbor innate anti-tumor immunity, and cytotoxic T cells all can participate in tumor suppression. The balance between pro- and anti-tumor leukocytes ultimately determines the behavior and fate of transformed cells; a multitude of human clinical studies have borne this out. Thus, detailed analysis of leukocyte subsets within the tumor microenvironment has become increasingly important. Here, we describe a method for analyzing infiltrating leukocyte subsets present in the tumor microenvironment in a mouse tumor model. Mouse B16 melanoma tumor cells were inoculated subcutaneously in C57BL/6 mice. At a specified time, tumors and surrounding skin were resected en bloc and processed into single cell suspensions, which were then stained for multi-color flow cytometry. Using a variety of leukocyte subset markers, we were able to compare the relative percentages of infiltrating leukocyte subsets between control and chemerin-expressing tumors. Investigators may use such a tool to study the immune presence in the tumor microenvironment and when combined with traditional caliper size measurements of tumor growth, will potentially allow them to elucidate the impact of changes in immune composition on tumor growth. Such a technique can be applied to any tumor model in which the tumor and its microenvironment can be resected and processed.     

白细胞弹性蛋白酶抑制剂

人白细胞弹性蛋白酶广泛参与体内的组织损伤反应,与炎症反应、自身免疫、肿瘤形成和转移等有密切关系。目前人白细胞弹性蛋白酶抑制剂已成为新药开发的热点,具有很高的应用价值,其中西维来司钠已经成功进入市场。本文对近几年发现的人白细胞弹性蛋白酶抑制剂的结构及其作用进行综述。     

Leukocyte-mediated cell dissemination and metastasis: findings from multiple types of human tumors

Our previous studies revealed that leukocyte infiltration could trigger human breast and prostate tumor invasion through focal disruptions of the tumor capsule, which selectively favors monoclonal proliferation of tumor progenitors or a biologically more aggressive cell clone overlying the focal disruptions. Our current study, involving multiple types of human tumors, further shows that leukocyte infiltration could also trigger tumor metastasis through the following pathways: [1] more leukocytes migrate to focally disrupted tumor capsules, which forms leukocyte aggregates surrounding newly formed tumor cell clusters, [2] the physical movement of leukocytes into proliferating tumor cells disrupts the intercellular junctions and cell-surface adhesion molecules, causing the disassociation of tumor cells from the tumor core, [3] leukocytes are conjoined with some of these tumor cells through plasma membrane fusion, creating tumor cell-leukocyte chimeras (TLCs), and [4] the leukocyte of TLCs impart migratory capacity to associated tumor cell partners, physically dragging them to different tissue sites. Our findings suggest a novel pathway for tumor cell dissemination from the primary sites and the subsequent journey to new sites. Our findings also provide a unique explanation for the cellular mechanism of leukocytes on tumor invasion and metastasis. If confirmed, our hypothesis and technical approach may significantly facilitate early detection and intervention of tumor invasion and metastasis.     

Ability of renal carcinoma tissue extract to induce leukocyte migration inhibition in patients with nonmetastatic renal carcinoma: Correlation with clinical and histopathological findings

Summary Soluble extracts prepared from 24 renal carcinomas were tested for their ability to induce inhibition of migration of leukocytes from 27 patients with nonmetastatic hypernephroma using the capillary tube leukocyte migration technique. No correlations were found between the histopathology of the carcinomas tested and this ability. However, highly significant correlations were demonstrated between the existence of nonmetastatic tumor and tumor-directed, cell-mediated hypersensitivity in the tumor donors and the ability of tumor tissue extracts from such patients to induce leukocyte migration inhibition in allogeneic tests.The capacity of renal carcinoma tissue extracts to induce leukocyte migration inhibition in renal carcinoma patients seems in allogeneic combinations to be an in vitro correlate of in vivo tumor antigenicity.     

Xenogeneic immunotherapy of transplantable guinea pig hepatoma with primate leukocyte lysates

Summary Injection of leukocyte lysates prepared from rhesus monkeys xenografted with syngeneic strain-2 guinea pig line 10 hepatoma cells had the ability to increase survival times in guinea pigs receiving lethal, metastasizing doses of the tumor cells. Immunotherapy of the line 10 hepatoma with these xenogeneic anti-line 10 leukocyte lysates resulted in 5 out of 11, or 45.4%, of the animals surviving tumor challenge. Substantially increased survival times were observed in groups of animals treated with lysates from normal or anti-line 1 hepatoma sensitized rhesus monkeys as well. All survivors possessed in vivo skin reactivity and in vitro positive cell-migration inhibition against the line 10 antigen and purified protein derivative. The survivors exhibited negative or marginal immune reactivity against line 1 antigen, strain-2 salt-extracted liver antigen, and a nonspecific antigen, keyhole limpet hemocyanin (KLH). Intact leukocyte lysates from line 10 xenografted baboons, rhesus monkey lysate dialysates, RNA extracts of leukocyte lysates, or lysates of nonlymphoid liver cells obtained from line 10 sensitized rhesus monkeys all failed to extend survival times significantly in strain-2 guinea pigs bearing the line 10 tumor.     

Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors

For successful application of chimeric antigen receptor (CAR) T cell therapy in solid tumors, major hurdles have to be overcome. CAR T cells have to cross the vascular barrier, which is hampered by the anergic state of the tumor vasculature, characterized by suppressed levels of leukocyte adhesion molecules on the endothelium. Additional immunosuppressive mechanisms in the solid tumor microenvironment can affect infiltration, activity and persistence of CAR T cells. Redirecting CAR T cells towards the tumor vasculature poses a possible solution, as molecular targets of tumor endothelial cells can be directly engaged from within the blood.In this review, we discuss recent advances in CAR T cell therapy against solid tumors, with a focus on targeting the tumor vasculature. Furthermore, we discuss opportunities to overcome challenges and barriers through engineering of CAR T cells to enhance trafficking, safety and efficacy.     

Hybrid recombinant human leukocyte interferon inhibits differentiation in murine B-16 melanoma cells

We have investigated the effects of recombinant human leukocyte interferons (IFN-alpha A and IFN-alpha D) and various hybrid recombinant human leukocyte interferons on differentiation in B-16 mouse melanoma cells. Inhibition of both spontaneous and melanocyte hormone stimulated differentiation was observed with one hybrid construct, IFN-alpha A/D (Bgl) consisting of amino acids 1 to 62 from IFN-alpha A and amino acids 64 to 166 from IFN-alpha D. In contrast, the parental human interferons, IFN-alpha A and IFN-alpha D, when used alone or in combination, as well as other hybrid human leukocyte interferons, did not cause significant inhibition of melanogenesis in B-16 mouse cells. The tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) also inhibited B-16 differentiation and the combination of TPA with IFN-alpha A/D (Bgl) or mouse L-cell interferon was synergistic in delaying melanogenesis. These studies indicate that the IFN-alpha A/D (Bgl) hybrid that exhibits antiviral activity on mouse cells can also inhibit differentiation of murine cells.     

Anti-angiogenesis: making the tumor vulnerable to the immune system

Ongoing angiogenesis has been shown to possess immune suppressive activity through several mechanisms. One of these mechanisms is the suppression of adhesion receptors, such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin-adhesion molecules involved in leukocyte interactions-on the vascular endothelium. This phenomenon, when happening to the tumor endothelium, supports tumor growth due to escape from immunity. Since angiogenesis has this immune suppressive effect, it has been hypothesized that inhibition of angiogenesis may circumvent this problem. In vitro and in vivo data now show that several angiogenesis inhibitors are able to normalize endothelial adhesion molecule expression in tumor blood vessels, restore leukocyte vessel wall interactions, and enhance the inflammatory infiltrate in tumors. It is suggested that such angiogenesis inhibitors can make tumors more vulnerable for the immune system and may therefore be applied to facilitate immunotherapy approaches for the treatment of cancer.